DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JAKAFI

« Back to Dashboard

All Clinical Trials for JAKAFI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01251965	Phase l/II Study of Ruxolitinib for Acute Leukemia	Completed	Incyte Corporation	Phase 1/Phase 2	2010-12-01	The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01251965	Phase l/II Study of Ruxolitinib for Acute Leukemia	Completed	M.D. Anderson Cancer Center	Phase 1/Phase 2	2010-12-01	The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01732445	Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2013-04-01	This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01732445	Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis	Active, not recruiting	Mayo Clinic	Phase 2	2013-04-01	This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01751425	Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)	Recruiting	Incyte Corporation	Phase 1/Phase 2	2013-07-01	This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
NCT01751425	Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)	Recruiting	M.D. Anderson Cancer Center	Phase 1/Phase 2	2013-07-01	This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
NCT01758588	Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis	Active, not recruiting	Merck Sharp & Dohme Corp.	Phase 2	2013-01-01	The purpose of this study is to look at the effectiveness of giving patients who have been newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to the widely employed "watch and wait" (best supportive care) approach for early stage PMF, in which patients are followed closely and treatment initiated only if the disease progresses.

Clinical Trial Conditions for JAKAFI

Condition Name

Condition Name for JAKAFI
Intervention	Trials
Myelofibrosis	11
Leukemia	8
Primary Myelofibrosis	6
Secondary Myelofibrosis	4

Condition MeSH

Condition MeSH for JAKAFI
Intervention	Trials
Primary Myelofibrosis	18
Leukemia	14
Leukemia, Lymphoid	7
Thrombocytosis	7

Clinical Trial Locations for JAKAFI

Trials by Country

Trials by Country for JAKAFI
Location	Trials
United States	123
China	3
Canada	3
Singapore	1

Trials by US State

Trials by US State for JAKAFI
Location	Trials
Texas	15
Arizona	8
New York	8
Massachusetts	7
California	6

Clinical Trial Progress for JAKAFI

Clinical Trial Phase

Clinical Trial Phase for JAKAFI
Clinical Trial Phase	Trials
Phase 3	2
Phase 2/Phase 3	1
Phase 2	28

Clinical Trial Status

Clinical Trial Status for JAKAFI
Clinical Trial Phase	Trials
Recruiting	25
Not yet recruiting	24
Active, not recruiting	2

Clinical Trial Sponsors for JAKAFI

Sponsor Name

Sponsor Name for JAKAFI
Sponsor	Trials
Incyte Corporation	27
National Cancer Institute (NCI)	10
M.D. Anderson Cancer Center	10

Sponsor Type

Sponsor Type for JAKAFI
Sponsor	Trials
Other	48
Industry	42
NIH	11